Patents by Inventor Tieming Zhao
Tieming Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11949525Abstract: A server system receives a group operation request transmitted by a client. The group operation request is generated by the client in response to a trigger operation of a target group chat function, and includes a target identity and a target group chat function identifier. The server system determines a target group chat function use permission corresponding to the target identity. In accordance with a determination, based on the target group chat function use permission and the target group chat function identifier, that a user corresponding to the target identity has a permission to use the target group chat function, the server system transmits group operation result information to the client.Type: GrantFiled: May 17, 2022Date of Patent: April 2, 2024Assignee: TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITEDInventors: Tieming Huang, Xiaoqiang Zhao, Hang Xiang, Bin Li, Linsheng Deng
-
Publication number: 20210032286Abstract: Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.Type: ApplicationFiled: August 21, 2020Publication date: February 4, 2021Inventors: Eric Wang, Hartmuth C. Kolb, Anna Katrin Szardenings, Changhui Liu, Joseph C. Walsh, Gang Chen, Anjana Sinha, Dhanalakshmi Kasi, Chul Yu, Umesh B. Gangadharmath, Wei Zhang, Tieming Zhao, Vani P. Mocharla
-
Publication number: 20210024574Abstract: Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.Type: ApplicationFiled: August 21, 2020Publication date: January 28, 2021Inventors: Eric Wang, Hartmuth C. Kolb, Anna Katrin Szardenings, Changhui Liu, Joseph C. Walsh, Gang Chen, Anjana Sinha, Dhanalakshmi Kasi, Chul Yu, Umesh B. Gangadharmath, Wei Zhang, Tieming Zhao, Vani P. Mocharla
-
Patent number: 10894807Abstract: Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.Type: GrantFiled: May 9, 2018Date of Patent: January 19, 2021Assignee: Siemens Medical Solutions USA, Inc.Inventors: Eric Wang, Hartmuth C. Kolb, Anna Katrin Szardenings, Changhui Liu, Joseph C. Walsh, Gang Chen, Anjana Sinha, Dhanalakshmi Kasi, Chul Yu, Umesh B. Gangadharmath, Wei Zhang, Tieming Zhao, Vani P. Mocharla
-
Publication number: 20200377549Abstract: Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.Type: ApplicationFiled: August 21, 2020Publication date: December 3, 2020Inventors: Eric Wang, Hartmuth C. Kolb, Anna Katrin Szardenings, Changhui Liu, Joseph C. Walsh, Gang Chen, Anjana Sinha, Dhanalakshmi Kasi, Chul Yu, Umesh B. Gangadharmath, Wei Zhang, Tieming Zhao, Vani P. Mocharla
-
Publication number: 20180258134Abstract: Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.Type: ApplicationFiled: May 9, 2018Publication date: September 13, 2018Inventors: Eric Wang, Hartmuth C. Kolb, Anna Katrin Szardenings, Changhui Liu, Joseph C. Walsh, Gang Chen, Anjana Sinha, Dhanalakshmi Kasi, Chul Yu, Umesh B. Gangadharmath, Wei Zhang, Tieming Zhao, Vani P. Mocharla
-
Patent number: 10011632Abstract: Compounds for targeting and agents for imaging, Prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.Type: GrantFiled: August 21, 2012Date of Patent: July 3, 2018Assignee: Siemens Medical Solutions USA, Inc.Inventors: Eric Wang, Hartmuth C. Kolb, Anna Katrin Szardenings, Changhui Liu, Joseph C. Walsh, Gang Chen, Anjana Sinha, Dhanalakshmi Kasi, Chul Yu, Umesh B. Gangadharmath, Wei Zhang, Tieming Zhao, Vani P. Mocharla
-
Publication number: 20160304555Abstract: Compounds for targeting and agents for imaging, Prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.Type: ApplicationFiled: August 21, 2012Publication date: October 20, 2016Inventors: Eric WANG, Hartmuth C. KOLB, Anna Katrin INGS, Changhui LIU, Joseph C. WALSH, Gang CHEN, Anjana SINHA, Dhanalakshmi KASI, Chul YU, Umesh B. GANGADHARMATH, Wei ZHANG, Tieming ZHAO, Vani P. MOCHARLA
-
Patent number: 8486372Abstract: The present application is directed to radiolabeled cyclic polyazapeptides, pharmaceutical compositions comprising radiolabeled cyclic polyazapeptides, and methods of using the radiolabeled cyclic polyazapeptides. Such polyazapeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).Type: GrantFiled: May 23, 2011Date of Patent: July 16, 2013Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Kai Chen, Joseph C. Walsh, Dhanalakshmi Kasi, Vani P. Mocharla, Gang Chen, Qianwa Liang, Tieming Zhao
-
Patent number: 8420052Abstract: Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.Type: GrantFiled: July 24, 2009Date of Patent: April 16, 2013Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Wei Zhang, Umesh B. Gangadharmath, Dhanalakshmi Kasi, Kai Chen, Anjana Sinha, Eric Wang, Gang Chen, Peter J. H. Scott, Henry Clifton Padgett, Qianwa Liang, Zhiyong Gao, Tieming Zhao, Chunfang Xia, Vani P. Mocharla
-
Patent number: 8354092Abstract: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.Type: GrantFiled: August 25, 2010Date of Patent: January 15, 2013Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Dhanalakshmi Kasi, Vani P. Mocharla, Bing Wang, Umesh B. Gangadharmath, Brian A. Duclos, Kai Chen, Wei Zhang, Gang Chen, Henry Clifton Padgett, Farhad Karimi, Peter J. H. Scott, Zhiyong Gao, Qianwa Liang, Thomas Lee Collier, Tieming Zhao, Chunfang Xia
-
Patent number: 8043601Abstract: The present application is directed to radiolabeled cyclic polyazapeptides, pharmaceutical compositions comprising radiolabeled cyclic polyazapeptides, and methods of using the radiolabeled cyclic polyazapeptides. Such polyazapeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).Type: GrantFiled: July 25, 2008Date of Patent: October 25, 2011Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Kai Chen, Joseph C. Walsh, Dhanalakshmi Kasi, Vani P. Mocharla, Gang Chen, Qianwa Liang, Tieming Zhao
-
Publication number: 20110256057Abstract: The present application is directed to radiolabeled cyclic polyazapeptides, pharmaceutical compositions comprising radiolabeled cyclic polyazapeptides, and methods of using the radiolabeled cyclic polyazapeptides. Such polyazapeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).Type: ApplicationFiled: May 23, 2011Publication date: October 20, 2011Applicant: SIEMENS MEDICAL SOLUTIONS USA, INC.Inventors: Hartmuth C. Kolb, Kai Chen, Joseph C. Walsh, Dhanalakshmi Kasi, Vani P. Mocharla, Gang Chen, Qianwa Liang, Tieming Zhao
-
Patent number: 7977361Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.Type: GrantFiled: July 15, 2010Date of Patent: July 12, 2011Assignee: Siemens Medical Solutions USA, Inc.Inventors: Thomas Lee Collier, Brian A. Duclos, Umesh B. Gangadharmath, Zhiyong Gao, Farhad Karimi, Dhanalakshmi Kasi, Hartmuth C. Kolb, Qianwa Liang, Henry Clifton Padgett, Joseph C. Walsh, Tieming Zhao
-
Publication number: 20110091382Abstract: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.Type: ApplicationFiled: February 17, 2009Publication date: April 21, 2011Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Qianwa Liang, Brian A. Duclos, Wei Zhang, Peter J.H. Scott, Kai Chen, Zhiyong Gao, Tieming Zhao, Vani P. Mocharla, Dhanalakshmi Kasi, Gang Chen, Eric Wang, Anjana Sinha, Chunfang Xia, Henry Clifton Padgett, Farhad Karimi
-
Patent number: 7928210Abstract: Disclosed herein are novel radiolabeled nucleosides and methods for detecting cellular proliferation in a mammal, the method comprising administrating an effective amount of a radiolabeled nucleoside; the method comprising: a) administering to the mammal a diagnostically effective amount of the nucleoside to the mammal; b) allowing the nucleoside to distribute into the effective tissue; and c) imaging the tissue, wherein an increase in binding of the compound to tissue compared to a normal control level of binding indicates that the mammal is suffering from a disease involving cellular proliferation.Type: GrantFiled: March 3, 2008Date of Patent: April 19, 2011Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Robert M Yeh, Kai Chen, Umesh Gangadharmath, Brian Duclos, Vani P. Mocharla, Farhad Karimi, Henry C. Padgett, Qianwa Liang, Tieming Zhao
-
Publication number: 20110046378Abstract: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's DiseaseType: ApplicationFiled: February 17, 2009Publication date: February 24, 2011Applicant: SIEMENS MEDICAL SOLUTIONS USA, INC.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Qianwa Liang, Brian A. Duclos, Wei Zhang, Peter J.H. Scott, Kai Chen, Zhiyong Gao, Tieming Zhao, Vani P. Mocharla, Dhanalakshmi Kasi, Gang Chen, Eric Wang, Anjana Sinha, Chunfang Xia, Henry Clifton Padgett, Farhad Karimi
-
Publication number: 20110002850Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.Type: ApplicationFiled: July 15, 2010Publication date: January 6, 2011Applicant: SIEMENS MEDICAL SOLUTIONS USA, INC.Inventors: Thomas Lee Collier, Brian A. Duclos, Umesh B. Gangadharmath, Zhiyong Gao, Farhad Karimi, Dhanalakshmi Kasi, Hartmuth C. Kolb, Qianwa Liang, Henry Clifton Padgett, Joseph C. Walsh, Tieming Zhao
-
Publication number: 20100317842Abstract: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.Type: ApplicationFiled: August 25, 2010Publication date: December 16, 2010Applicant: SIEMENS MEDICAL SOLUTIONS USA, INC.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Dhanalakshmi Kasi, Vani P. Mocharla, Bing Wang, Umesh B. Gangadharmath, Brian A. Duclos, Kai Chen, Wei Zhang, Gang Chen, Henry Clifton Padgett, Farhad Karimi, Peter J.H. Scott, Zhiyong Gao, Qianwa Liang, Thomas Lee Collier, Tieming Zhao, Chunfang Xia
-
Patent number: 7829063Abstract: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.Type: GrantFiled: April 7, 2008Date of Patent: November 9, 2010Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Dhanalakshmi Kasi, Vani P. Mocharla, Bing Wang, Umesh B. Gangadharmath, Brian A. Duclos, Kai Chen, Wei Zhang, Gang Chen, Henry Clifton Padgett, Farhad Karimi, Peter J. H. Scott, Zhiyong Gao, Qianwa Liang, Thomas Lee Collier, Tieming Zhao, Chunfang Xia